The Fickle (and Unforgiving) Fashion of Antiretroviral Therapies:
Early treatment choices and their unintended consequences.
|No survival benefit found; resistant mutant associated with more rapid progression.|
|Double resistance after one year; reduced sensitivity to other nucleoside reverse transcriptase inhibitors.|
|Combination not proven superior to ddI monotherapy; AZT mutant not forestalled. Selection of multi-ddN resistant mutants.|
|Indinavir “break-throughs” highly resistant to other proteases; resistant mutants fully ‘fit.’|